Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.33 |
| ▸ | GABRP | O00591 | 1/20 | 0.32 |
| ▸ | GABRD | O14764 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.32 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.32 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.32 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.32 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.32 |
| ▸ | GABRE | P78334 | 1/20 | 0.32 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.32 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.32 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.32 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21813883 | 0.88 | NOTUM (0.33) | NOTUM | |
| SCHEMBL21814084 | 0.78 | POLB (0.32) | NOTUM | |
| SCHEMBL30845421 | 0.78 | POLB (0.32) | NOTUM | |
| SCHEMBL21814039 | 0.75 | KDM4E (0.41) | NOTUM | |
| SCHEMBL30845432 | 0.65 | UGT8 (0.43) | NOTUM | |
| SCHEMBL21813648 | 0.65 | UGT8 (0.43) | NOTUM | |
| SCHEMBL21813867 | 0.64 | KDM4E (0.41) | NOTUM | |
| SCHEMBL21813423 | 0.64 | NGFR (0.38) | NOTUM | |
| SCHEMBL21813941 | 0.64 | KDM4E (0.41) | NOTUM | |
| SCHEMBL5568741 | 0.63 | NPSR1 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3861000-A1 | THIENO[3,2-B]PYRIDINE DERIVATIVES AS UDP GLYCOSYLTRANSFERASE INHIBITORS AND METHODS OF USE | Genzyme Corporation (US) | 2021-08-11 | — | — | EP | disclosed |
| WO-2020072504-A1 | THIENO[3,2-B]PYRIDINE DERIVATIVES AS UDP GLYCOSYLTRANSFERASE INHIBITORS AND METHODS OF USE | GENZYME CORPORATION (US) | 2020-04-09 | — | — | WO | disclosed |
| US-20200102324-A1 | UDP GLYCOSYLTRANSFERASE INHIBITORS AND METHODS OF USE | GENZYME CORPORATION | 2020-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200102324-A1 | UDP GLYCOSYLTRANSFERASE INHIBITORS AND METHODS OF USE | MAN2B1, GAA, GBA1 | NOTUM 782/4885GABRP 3240/4885GABRD 1719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.